| Literature DB >> 32953385 |
Grant W Waterer1,2, Jordi Rello3,4,5.
Abstract
COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.Entities:
Keywords: ARDS; Coronavirus; Covid-19; Pneumonia; Precision medicine; RCT; SARS; Therapy
Year: 2020 PMID: 32953385 DOI: 10.1007/s40121-020-00338-x
Source DB: PubMed Journal: Infect Dis Ther ISSN: 2193-6382